• Patients with VTE in higher weight and BMI categories are frequently prescribed DOACs by the VA healthcare system
  • The use of DOACs, compared with warfarin, was not associated with an increase in bleeding events or recurrent VTE in these patients
  • These findings suggest that DOACs can be well tolerated and effective in this population, and may support broader adoption of pharmacy policies that promote careful patient selection and shared decision-making